NTHI Stock Forecast & Price Target

NeOnc Technologies Hldgs is attractive fundamentally because its POH-based platform tackles the hardest bottleneck in CNS oncology: getting effective drug levels across the blood-brain barrier while preserving safety. NEO100’s Phase 2a data are especially compelling, with 48.9% six-month PFS versus a 20% benchmark, median OS of 26.09 months, no major toxicities, and 21 of 24 patients being recurrent Grade IV, supporting clinical relevance in a population with no approved targeted therapy. NEO212 adds a second value driver through roughly 3X CNS exposure versus TMZ, a favorable FDA CMC interaction, and a financial base that included $8.8M net loss in 1Q26, $6.1M normalized cash operating expenses, and funding into September 2026.

NeOnc Technologies Hldgs is facing a weak fundamental profile, as the company posted a $14.2M net loss and a $14.1M net operating loss in 2Q26 while ending the quarter with only $2M in cash and equivalents, signaling limited financial flexibility. Its lead value driver, NEO212, may benefit from FDA alignment, but the required in vivo relative bioavailability study and additional manufacturing work add execution risk and pressure the development timeline. Given the company’s reliance on a single primary program and the need for a clearer updated timeline from management, the outlook remains negative because funding constraints and CMC complexity could continue to weigh on progress.